Headlines about Rosetta Genomics (NASDAQ:ROSG) have been trending somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rosetta Genomics earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 45.3224586952108 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several equities research analysts recently issued reports on ROSG shares. ValuEngine upgraded shares of Rosetta Genomics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Barrington Research downgraded shares of Rosetta Genomics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 18th.
ROSG stock remained flat at $$0.37 during mid-day trading on Friday. 24,632 shares of the company’s stock traded hands, compared to its average volume of 48,656. The firm has a market capitalization of $2.21, a P/E ratio of -0.04 and a beta of 0.47. Rosetta Genomics has a 1 year low of $0.23 and a 1 year high of $3.29.
In other Rosetta Genomics news, major shareholder Healthcare Master Fund Sabby bought 119,761 shares of the stock in a transaction dated Thursday, March 15th. The shares were bought at an average cost of $0.42 per share, with a total value of $50,299.62. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
TRADEMARK VIOLATION NOTICE: “Rosetta Genomics (ROSG) Given Media Sentiment Rating of 0.11” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/15/rosetta-genomics-rosg-given-media-sentiment-rating-of-0-11.html.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests.
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.